Drug Profile
Rifabutin
Alternative Names: Ansamycin; Ansatipin; Ansatipine; LM 427; MycobutinLatest Information Update: 08 Apr 2015
Price :
$50
*
At a glance
- Originator Pfizer
- Class Antibacterials; Antituberculars; Rifamycins
- Mechanism of Action Protein 50S ribosomal subunit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Mycobacterium avium complex infections
Most Recent Events
- 24 Jun 2018 Biomarkers information updated
- 01 Feb 2015 Pfizer and Ottawa Hospital Research Institute completes a phase I trial in healthy volunteers in Canada (NCT01894776)
- 07 Oct 2009 Launched for Mycobacterium avium complex infections in European Union (PO)